Ostatní
Návod 
BioMarin Pharmaceutical Inc.
BMRN
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
10.0B
Obrat
3B
Zisk
0B
Aktiva
8B
Dluh
1B
ROE
0%
ROA
0%
PE
31
PS
3
Cena 1R
51-74
⌀ Cena
56.83
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
29-04-2026
Poslední dividenda
Profil
Společnost BioMarin Pharmaceutical Inc. vyvíjí a komercializuje terapie pro lidi s vážnými a život ohrožujícími vzácnými onemocněními a zdravotními potížemi. Mezi jeho komerční produkty patří Vimizim, enzymová substituční léčba mukopolysacharidózy (MPS) IV typu A, lysozomální poruchy uchovávání; Naglazyme, rekombinantní forma N-acetylgalaktosamin- 4- sulfatázy u pacientů s MPS VI; a Kuvan, patentovaná syntetická perorální forma 6R-BH4, která se používá k léčbě pacientů s fenylketonurií (PKU), dědičným metabolickým onemocněním. Komerční produkty společnosti zahrnují také Palynziq, rekombinantní enzym fenylalanin amoniaklyázu, který se dodává subkutánní injekcí ke snížení koncentrací Phe v krvi; Brineura, rekombinantní humánní tripeptidylpeptidázu 1 pro léčbu pacientů s ceroidní lipofuscinózou typu 2, což je forma Battenovy choroby; Voxzogo, jedenkrát denně injekční analog natriuretického peptidu typu c pro léčbu achondroplazie; a Aldurazyme, purifikovaný protein určený pro léčbu achondroplazie být identické s přirozeně se vyskytující formou lidského enzymu alfa-L- iduronidázy. Kromě toho se u něj vyvíjí valoctokogen roxaparvovec, virový vektor přidružený k adenu, který je součástí klinické studie fáze III pro léčbu pacientů s těžkou hemofilií A; BMN 307, genová terapie zprostředkovaná AAV5, která probíhá v klinické studii fáze 1/2 s cílem normalizovat hladiny koncentrací Phe v krvi u pacientů s PKU; a BMN 255, který je součástí klinické studie fáze 1/2 pro léčbu primární hyperoxalurie. Společnost poskytuje služby specializovaným lékárnám, nemocnicím a vládním agenturám mimo USA, stejně jako distributorům a velkoobchodníkům s farmaceutickými výrobky ve Spojených státech, Evropě, Latinské Americe a na mezinárodní úrovni. Společnost BioMarin Pharmaceutical Inc. má licenční smlouvy a smlouvy o spolupráci se společnostmi Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. a Asubio Pharma Co., Ltd. Společnost byla založena v roce 1996 a má sídlo v San Rafael v Kalifornii.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
3040
Založení
1999-07-26
Podobné společnosti
$ 40.25
- $ 0.56
$ 23.89
- $ 0.66
$ 62.37
+ $ 1.36
$ 57.36
- $ 0.05
$ 68.88
+ $ 0.64
$ 487.29
- $ 1.97
$ 69.78
- $ 0.06
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 3,221.3 | 3,221.3 | 2,853.9 | 2,419.2 | 2,096.0 | 1,846.3 | 1,860.5 | 1,704.0 | 1,491.2 | 1,313.6 | 1,116.9 | 889.9 | 751.0 | 548.5 | 500.7 | 441.4 | 376.3 | |
| Cost of Revenues | 736.8 | 736.8 | 580.2 | 577.1 | 483.7 | 470.5 | 524.3 | 359.5 | 315.3 | 241.8 | 209.6 | 152.0 | 129.8 | 95.7 | 91.8 | 84.0 | 70.3 | |
| Gross Profit | 2,484.4 | 2,484.4 | 2,273.7 | 1,842.2 | 1,612.4 | 1,375.8 | 1,336.2 | 1,344.6 | 1,175.9 | 1,071.9 | 907.2 | 737.9 | 621.3 | 452.7 | 408.9 | 357.3 | 306.0 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 874.6 | 776.1 | 825.4 | 745.1 | 747.3 | 745.7 | 712.0 | 648.8 | 646.2 | 586.0 | |
| Cost of Revenues | 295.1 | 140.1 | 150.1 | 151.6 | 136.1 | 188.5 | 130.5 | 125.2 | 135.5 | 140.4 | |
| Gross Profit | 579.5 | 636.0 | 675.3 | 593.6 | 611.2 | 557.3 | 581.6 | 523.7 | 510.7 | 445.5 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 746.8 | 649.6 | 628.8 | 628.1 | 715.0 | 696.3 | 610.8 | 661.9 | 634.8 | 461.5 | 354.8 | 302.2 | 214.4 | 147.3 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 937.3 | 854.0 | 759.4 | 737.7 | 680.9 | 604.4 | 554.3 | 476.6 | 402.3 | 302.2 | 235.4 | 198.2 | 175.4 | 151.7 | |
| Depreciation & Amortization | 79.6 | 79.6 | 96.4 | 104.4 | 102.0 | 108.0 | 90.4 | 103.2 | 48.8 | 46.5 | -27.0 | -17.7 | 18.0 | 47.3 | 18.7 | 36.1 | 27.7 | |
| Total Operating Expenses | 1,950.9 | 1,950.9 | 1,789.5 | 1,746.3 | 1,570.8 | 1,458.1 | 1,432.4 | 1,470.0 | 1,349.5 | 1,211.6 | 1,111.5 | 1,019.4 | 781.7 | 608.8 | 519.1 | 389.8 | 299.0 | |
| Operating Income | 533.5 | 533.5 | 484.2 | 194.4 | 57.5 | -60.0 | -96.3 | -125.5 | -123.5 | -14.7 | -803.4 | -110.7 | -92.9 | -156.0 | -110.2 | -33.9 | 0.5 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 206.3 | 191.3 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 275.0 | 231.4 | ||
| Depreciation & Amortization | 20.4 | 18.5 | 18.6 | 22.1 | 23.6 | 19.0 | 26.5 | 27.4 | 26.9 | 25.7 | ||
| Total Operating Expenses | 500.1 | 682.7 | 398.4 | 369.7 | 449.8 | 443.4 | 461.1 | 435.2 | 496.5 | 422.7 | ||
| Operating Income | 79.4 | -46.7 | 276.9 | 223.9 | 161.4 | 113.9 | 120.5 | 88.5 | 14.2 | 22.8 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 74.9 | 74.9 | 74.9 | 58.3 | 18.0 | 10.5 | 16.6 | 22.7 | 22.8 | 14.9 | 7.5 | 4.5 | 5.9 | 3.1 | 2.6 | 2.9 | 4.1 | |
| Interest Expense | 10.9 | 10.9 | 12.7 | 17.3 | 16.0 | 15.3 | 29.3 | 23.5 | 43.7 | 42.7 | 39.5 | 38.2 | 36.6 | 10.4 | 7.6 | 8.3 | 10.3 | |
| Other Expense | -51.0 | -51.0 | 57.5 | -5.9 | 92.0 | -15.3 | 53.9 | 30.6 | 51.7 | 131.7 | -594.7 | 160.7 | 66.9 | -0.2 | -3.0 | -5.8 | -22.2 | |
| IBT | 482.5 | 482.5 | 541.8 | 188.6 | 149.6 | -75.4 | -42.3 | -94.8 | -142.7 | -35.9 | -831.1 | -154.7 | -124.9 | -176.5 | -118.3 | -43.6 | -21.5 | |
| Income Tax Expense | 133.6 | 133.6 | 114.9 | 20.9 | 8.0 | -11.3 | -901.4 | -71.0 | -65.5 | 81.2 | -200.8 | 17.1 | 9.1 | -0.2 | -3.9 | 10.2 | -227.3 | |
| Net Income | 348.9 | 348.9 | 426.9 | 167.6 | 141.6 | -64.1 | 859.1 | -23.8 | -77.2 | -117.0 | -630.2 | -171.8 | -134.0 | -176.4 | -114.3 | -53.8 | 205.8 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 19.2 | 17.9 | 18.8 | 19.0 | 17.7 | 18.1 | 19.8 | 19.4 | 18.0 | 15.7 | ||
| Interest Expense | 2.8 | 2.6 | 2.7 | 2.9 | 2.6 | 3.0 | 3.6 | 3.5 | 6.1 | 3.8 | ||
| Other Expense | -106.5 | 20.4 | 21.0 | 14.2 | 8.2 | 20.5 | 11.7 | 17.1 | 5.1 | 11.1 | ||
| IBT | -27.2 | -26.3 | 297.9 | 238.1 | 169.6 | 134.4 | 132.1 | 105.5 | 19.3 | 41.7 | ||
| Income Tax Expense | 19.4 | 4.4 | 57.3 | 52.4 | 44.7 | 28.4 | 25.0 | 16.9 | -1.0 | 1.3 | ||
| Net Income | -46.6 | -30.7 | 240.5 | 185.7 | 124.9 | 106.1 | 107.2 | 88.7 | 20.4 | 40.4 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | $-1.28 | $-0.95 | $-0.48 | $1.99 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.79 | $-1.07 | $-0.92 | $-1.28 | $-0.95 | $-0.48 | $1.73 | |
| Shares Outstanding | 191.8 | 191.8 | 190.0 | 187.8 | 185.3 | 182.9 | 180.8 | 179.0 | 177.1 | 174.4 | 166.0 | 160.0 | 146.3 | 137.8 | 120.3 | 112.1 | 103.1 | |
| Diluted Shares Outstanding | 197.4 | 197.4 | 196.7 | 191.6 | 189.0 | 182.9 | 191.7 | 179.0 | 177.3 | 174.4 | 166.2 | 160.0 | 146.3 | 137.8 | 120.3 | 112.1 | 125.7 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.11 | $0.21 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.11 | $0.21 | ||
| Shares Outstanding | 191.8 | 192.0 | 191.4 | 191.0 | 190.7 | 190.4 | 190.1 | 188.9 | 188.5 | 188.2 | ||
| Diluted Shares Outstanding | 197.4 | 192.0 | 196.6 | 196.5 | 196.6 | 197.1 | 200.5 | 199.3 | 191.8 | 191.2 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 972.2 | 942.8 | 755.1 | 724.5 | 587.3 | 649.2 | 437.4 | 494.0 | 598.0 | 408.3 | 397.0 | 875.5 | 568.8 | 180.5 | 46.3 | 88.1 | |
| Short Term Investments | 252.2 | 194.9 | 318.7 | 567.0 | 426.6 | 416.2 | 316.4 | 590.3 | 797.9 | 381.3 | 195.6 | 69.7 | 215.9 | 270.2 | 148.8 | 186.0 | |
| Total Cash & ST Investments | 1,224.4 | 1,137.7 | 1,073.8 | 1,291.5 | 1,013.9 | 1,065.4 | 753.8 | 1,084.3 | 1,396.0 | 789.7 | 592.6 | 945.2 | 784.7 | 450.7 | 195.1 | 274.1 | |
| Accounts Receivable | 691.2 | 660.5 | 633.7 | 461.3 | 373.4 | 448.4 | 377.4 | 342.6 | 261.4 | 215.3 | 165.0 | 144.5 | 117.8 | 109.1 | 104.8 | 86.6 | |
| Inventory | 1,183.6 | 1,232.7 | 1,107.2 | 894.1 | 776.7 | 698.5 | 680.3 | 530.9 | 475.8 | 355.1 | 271.7 | 199.5 | 162.6 | 128.7 | 130.1 | 109.7 | |
| Other Current Assets | 160.4 | 201.5 | 141.4 | 104.5 | 110.4 | 129.9 | 130.7 | 98.4 | 74.0 | 61.7 | 60.4 | 105.3 | 41.7 | 25.5 | 39.8 | 33.9 | |
| Total Current Assets | 3,259.6 | 3,232.4 | 2,956.1 | 2,751.5 | 2,274.4 | 2,342.2 | 1,942.1 | 2,056.2 | 2,207.1 | 1,421.8 | 1,089.6 | 1,425.6 | 1,137.4 | 743.5 | 469.8 | 504.3 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 1,250.1 | 1,213.8 | 1,048.8 | 942.8 | 675.4 | 972.2 | 747.0 | 755.1 | 785.4 | 694.4 | |
| Short Term Investments | 227.7 | 218.3 | 223.5 | 194.9 | 255.0 | 252.2 | 299.6 | 318.7 | 340.4 | 476.6 | |
| Total Cash & ST Investments | 1,477.8 | 1,432.1 | 1,272.3 | 1,137.7 | 930.4 | 1,224.4 | 1,046.6 | 1,073.8 | 1,125.8 | 1,171.0 | |
| Accounts Receivable | 790.3 | 855.9 | 739.2 | 660.5 | 777.5 | 691.2 | 637.2 | 633.7 | 572.5 | 610.2 | |
| Inventory | 1,382.2 | 1,340.2 | 1,274.8 | 1,232.7 | 1,179.3 | 1,183.6 | 1,138.0 | 1,107.2 | 1,032.2 | 975.5 | |
| Other Current Assets | 204.3 | 177.2 | 181.5 | 201.5 | 169.3 | 160.4 | 163.3 | 141.4 | 224.8 | 193.4 | |
| Total Current Assets | 3,854.5 | 3,805.3 | 3,467.9 | 3,232.4 | 3,056.6 | 3,259.6 | 2,985.0 | 2,956.1 | 2,955.3 | 2,950.1 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 1,052.9 | 1,043.0 | 1,112.2 | 1,073.4 | 1,035.5 | 1,032.5 | 1,010.9 | 948.7 | 896.7 | 798.8 | 704.2 | 523.5 | 319.3 | 284.5 | 269.0 | 221.9 | |
| Goodwill | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 197.0 | 197.0 | 197.0 | 197.0 | 197.0 | 54.3 | 54.3 | 51.5 | 51.5 | 53.4 | |
| Intangible Assets | 265.5 | 255.3 | 294.7 | 338.6 | 388.7 | 417.3 | 456.6 | 491.8 | 517.5 | 553.8 | 684.0 | 156.6 | 163.1 | 163.0 | 180.3 | 103.6 | |
| Long-Term Investments | 567.7 | 521.2 | 611.1 | 333.8 | 507.8 | 285.5 | 412.0 | 235.9 | 385.8 | 572.7 | 425.7 | 98.9 | 281.5 | 117.1 | 94.9 | 129.3 | |
| Other Long-Term Assets | 180.1 | 251.4 | 125.5 | 176.2 | 151.8 | 142.2 | 122.0 | 36.6 | 29.9 | 32.8 | 408.6 | 65.3 | 143.2 | 16.6 | 15.5 | 14.2 | |
| Total Long-Term Assets | 3,807.5 | 3,756.5 | 3,885.5 | 3,623.6 | 3,728.9 | 3,505.8 | 2,747.9 | 2,370.9 | 2,426.0 | 2,601.9 | 2,639.7 | 1,064.8 | 1,111.8 | 858.2 | 833.9 | 758.4 | |
| Total Assets | 7,067.1 | 6,988.9 | 6,841.6 | 6,375.1 | 6,003.3 | 5,848.0 | 4,690.0 | 4,427.1 | 4,633.1 | 4,023.7 | 3,729.4 | 2,490.5 | 2,249.2 | 1,601.6 | 1,303.7 | 1,262.6 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 1,038.2 | 1,030.4 | 1,032.6 | 1,043.0 | 1,045.4 | 1,052.9 | 1,060.4 | 1,066.1 | 1,067.2 | 1,067.3 | |
| Goodwill | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | 196.2 | |
| Intangible Assets | 233.1 | 239.6 | 247.3 | 255.3 | 260.9 | 265.5 | 279.7 | 294.7 | 302.5 | 310.3 | |
| Long-Term Investments | 512.9 | 508.6 | 506.7 | 521.2 | 562.0 | 557.1 | 620.6 | 611.1 | 548.0 | 385.8 | |
| Other Long-Term Assets | 270.8 | 249.2 | 235.7 | 251.4 | 199.3 | 190.8 | 184.8 | 171.5 | 165.1 | 144.2 | |
| Total Long-Term Assets | 3,760.3 | 3,651.0 | 3,679.1 | 3,756.5 | 3,794.6 | 3,807.5 | 3,887.7 | 3,885.5 | 3,802.9 | 3,613.1 | |
| Total Assets | 7,614.9 | 7,456.3 | 7,147.0 | 6,988.9 | 6,851.2 | 7,067.1 | 6,872.7 | 6,841.6 | 6,758.2 | 6,563.2 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 257.4 | 235.4 | 315.5 | 231.2 | 193.0 | 191.4 | 570.6 | 437.3 | 401.9 | 370.5 | 392.5 | 235.7 | 95.3 | 147.1 | 12.2 | 5.0 | |
| Short-Term Debt | 505.5 | 23.1 | 502.7 | 10.4 | 10.5 | 11.8 | 361.9 | 0.0 | 360.9 | 22.5 | 0.0 | 0.0 | 0.0 | 23.4 | 0.0 | 75.6 | |
| Other Current Liabilities | 302.5 | 334.6 | 351.6 | 346.6 | 329.4 | 289.2 | -13.0 | 86.0 | 53.6 | 46.3 | 52.9 | 0.0 | 88.0 | 77.8 | 81.9 | 3.1 | |
| Current Liabilities | 1,067.3 | 607.0 | 1,177.0 | 588.9 | 539.8 | 492.5 | 932.5 | 523.2 | 816.5 | 439.3 | 445.5 | 235.7 | 183.3 | 170.4 | 94.1 | 83.8 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 389.7 | 310.8 | 293.8 | 235.4 | 312.3 | 257.4 | 292.2 | 315.5 | 301.4 | 277.9 | |
| Short-Term Debt | 0.0 | 7.7 | 6.3 | 7.6 | 8.1 | 505.5 | 502.9 | 502.7 | 502.7 | 8.3 | |
| Other Current Liabilities | 408.8 | 352.3 | 304.2 | 350.1 | 371.9 | 283.6 | 281.5 | 351.6 | 347.9 | 292.7 | |
| Current Liabilities | 798.4 | 684.2 | 628.2 | 607.0 | 715.7 | 1,067.3 | 1,087.9 | 117.7 | 1,163.2 | 597.2 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 594.1 | 626.4 | 593.1 | 1,083.0 | 1,079.1 | 1,075.1 | 486.2 | 830.4 | 813.5 | 660.8 | 662.3 | 658.0 | 655.6 | 324.9 | 348.3 | 377.5 | |
| Capital Leases | 10.7 | 7.6 | 8.8 | 10.4 | 10.5 | 11.8 | 10.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 143.5 | 166.3 | 150.4 | 33.3 | 35.1 | 36.5 | |
| Total Liabilities | 1,780.8 | 1,331.0 | 1,890.1 | 1,771.9 | 1,732.6 | 1,742.0 | 1,567.7 | 1,459.2 | 1,824.5 | 1,257.4 | 1,328.5 | 962.6 | 908.2 | 585.9 | 530.6 | 545.4 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 596.7 | 596.2 | 595.7 | 595.1 | 594.6 | 594.1 | 593.6 | 593.1 | 592.6 | 1,085.0 | |
| Capital Leases | 0.0 | 7.7 | 6.3 | 7.6 | 8.1 | 10.7 | 8.6 | 38.1 | 9.3 | 8.3 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 1,558.2 | 1,429.2 | 1,353.5 | 1,331.0 | 1,437.8 | 1,780.8 | 1,798.9 | 1,890.1 | 1,861.3 | 1,780.3 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Retained Earnings | -425.7 | -194.7 | -621.6 | -789.2 | -925.7 | -861.6 | -1,720.7 | -1,694.1 | -1,637.5 | -1,520.5 | -1,021.6 | -849.8 | -715.8 | -539.4 | -425.1 | -371.3 | |
| Comprehensive Income | 15.1 | 61.7 | -38.6 | -3.9 | 14.4 | -16.1 | 20.2 | 5.3 | -23.0 | 12.8 | 21.0 | 27.5 | 5.0 | -0.2 | 4.9 | 0.2 | |
| Total Common Equity | 5,286.3 | 5,658.0 | 4,951.5 | 4,603.2 | 4,270.7 | 4,106.0 | 3,122.4 | 2,967.9 | 2,808.7 | 2,766.3 | 2,400.8 | 1,527.9 | 1,341.0 | 1,015.8 | 773.0 | 717.3 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |
| Retained Earnings | 200.8 | 231.5 | -9.0 | -194.7 | -319.6 | -425.7 | -532.9 | -621.6 | -641.9 | -682.3 | |
| Comprehensive Income | -45.2 | -44.6 | 19.2 | 61.7 | 4.7 | 26.8 | -1.0 | -28.8 | 6.3 | -18.6 | |
| Total Common Equity | 6,056.7 | 6,027.1 | 5,793.5 | 5,658.0 | 5,413.4 | 5,286.3 | 5,073.8 | 4,951.5 | 4,896.9 | 4,782.8 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 1,099.6 | 649.5 | 1,095.8 | 1,083.0 | 1,079.1 | 1,075.1 | 848.1 | 830.4 | 1,174.5 | 683.2 | 662.3 | 658.0 | 655.6 | 348.2 | 348.3 | 377.5 | |
| Book Value | 5,286.3 | 5,658.0 | 4,951.5 | 4,603.2 | 4,270.7 | 4,106.0 | 3,122.4 | 2,967.9 | 2,808.7 | 2,766.3 | 2,400.8 | 1,527.9 | 1,341.0 | 1,015.8 | 773.0 | 717.3 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 6,056.7 | 6,027.1 | 5,793.5 | 5,658.0 | 5,413.4 | 5,286.3 | 5,073.8 | 4,951.5 | 4,896.9 | 4,782.8 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 256.6 | 348.9 | 426.9 | 167.6 | 141.6 | -64.1 | 859.1 | -23.8 | -77.2 | -117.0 | -630.2 | -171.8 | -134.0 | -176.4 | -114.3 | -53.8 | 205.8 | |
| Depreciation & Amortization | 106.4 | 79.6 | 96.4 | 104.4 | 102.0 | 108.0 | 105.2 | 105.3 | 95.7 | 87.9 | 96.9 | 47.2 | 56.7 | 47.3 | 45.3 | 36.1 | 27.7 | |
| Stock-Based Compensation | 209.4 | 181.4 | 201.6 | 207.1 | 196.3 | 197.3 | 189.7 | 159.9 | 148.8 | 140.3 | 134.6 | 111.5 | 88.2 | 66.2 | 47.3 | 43.9 | 38.4 | |
| Change Working Capital | -229.5 | -108.7 | -216.4 | -336.5 | -96.4 | 66.0 | -224.4 | -101.1 | -49.4 | -94.0 | -160.3 | 46.3 | -30.3 | -23.1 | 33.1 | -25.1 | -42.1 | |
| Change In Accounts Receivable | -100.7 | -228.1 | -57.9 | -190.4 | -82.0 | 65.6 | -59.0 | -37.9 | -54.3 | -25.3 | -51.5 | -16.4 | -26.7 | -8.8 | -4.2 | -18.5 | -13.0 | |
| Change In Accounts Payable | 39.7 | 66.1 | -32.2 | 68.9 | 59.0 | 15,689.0 | -68.7 | 50.1 | 20.6 | 24.8 | -33.9 | 116.1 | 36.5 | 8.3 | 33.9 | 12.7 | 5.4 | |
| Change In Inventories | -148.0 | 119.2 | -63.5 | -157.1 | -68.3 | -35.1 | -61.2 | -107.6 | -23.7 | -96.9 | -64.5 | -51.0 | -36.8 | -33.9 | 1.4 | -20.4 | -31.0 | |
| Other Non-cash Items | 655.5 | 278.1 | 8.3 | 61.6 | -115.5 | 12.9 | 44.7 | -9.2 | -29.3 | -70.3 | 559.2 | -178.1 | -28.7 | 35.5 | 16.2 | 13.3 | 19.5 | |
| Cash from Operations | 328.9 | 0.0 | 0.0 | 159.3 | 175.9 | 304.5 | 85.4 | 48.3 | 20.2 | -8.8 | -227.8 | -221.7 | -73.5 | -59.6 | 17.6 | 18.8 | 18.7 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 139.1 | -30.7 | 426.2 | 185.7 | 124.9 | 106.1 | 107.2 | 88.7 | 20.4 | 40.4 | |
| Depreciation & Amortization | 20.4 | 18.5 | 18.6 | 22.1 | 23.6 | 19.0 | 26.5 | 27.4 | 26.9 | 25.7 | |
| Stock-Based Compensation | 46.9 | 49.3 | 47.5 | 37.7 | 51.9 | 43.5 | 47.9 | 58.2 | 54.9 | 48.4 | |
| Change Working Capital | 20.9 | 118.9 | -158.1 | -90.5 | -83.2 | 39.1 | -66.9 | -105.4 | -97.1 | 39.9 | |
| Change In Accounts Receivable | -120.7 | 48.7 | -98.5 | -57.6 | 72.5 | -74.4 | -52.7 | -3.4 | -58.5 | 13.9 | |
| Change In Accounts Payable | -53.3 | 116.4 | 5.8 | -2.7 | -100.3 | 122.3 | 4.7 | -59.0 | 12.5 | 81.4 | |
| Change In Inventories | 218.0 | -26.3 | -48.1 | -24.3 | -34.3 | 18.2 | -30.6 | -16.8 | -59.1 | -41.5 | |
| Other Non-cash Items | -128.4 | 226.4 | -182.3 | -9.0 | 25.9 | 1.7 | 2.9 | -22.2 | 261.0 | 42.2 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.5 | 135.6 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -116.1 | -103.0 | -85.4 | -96.7 | -131.5 | -119.2 | -137.5 | -163.4 | -144.6 | -199.2 | -148.4 | -227.7 | -118.8 | -65.1 | -44.6 | -154.2 | -49.5 | |
| Acquisitions | 24.1 | -285.2 | 0.0 | 0.0 | 0.0 | -23.6 | -23.2 | 6.6 | 50.0 | 125.0 | -2.8 | -910.1 | -1.1 | -10.8 | -1.7 | 81.0 | -33.0 | |
| Investments | -619.9 | -355.9 | -410.3 | -868.5 | -611.8 | -937.1 | -538.4 | -632.0 | -634.8 | -655.4 | -699.7 | -876.5 | -559.3 | -395.0 | -387.2 | -217.3 | -225.3 | |
| Sales of Investment | 691.4 | 337.8 | 633.0 | 864.9 | 620.0 | 691.0 | 555.8 | 740.2 | 993.7 | 426.0 | 367.6 | 424.7 | 808.3 | 288.6 | 237.8 | 282.0 | 206.4 | |
| Other Investing Activities | 97.7 | 0.0 | 0.0 | -10.9 | 103.3 | 22.7 | 89.6 | 17.6 | 0.0 | -1.8 | -0.7 | 410.0 | 65.5 | -116.5 | 0.0 | -81.0 | 0.0 | |
| Cash from Investing | -34.5 | 0.0 | 0.0 | -111.2 | -20.0 | -366.3 | -53.6 | -31.0 | 264.4 | -305.5 | -484.0 | -1,179.6 | 194.6 | -298.8 | -195.6 | -89.6 | -101.3 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -40.7 | -33.8 | -17.1 | -16.8 | -19.5 | -18.5 | -21.3 | -26.1 | -36.7 | -23.4 | |
| Acquisitions | 0.0 | -285.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24.1 | |
| Investments | -42.6 | -110.8 | -113.2 | -89.3 | -57.9 | -156.9 | -73.8 | -121.7 | -141.5 | -283.0 | |
| Sales of Investment | 43.3 | 98.8 | 117.9 | 77.8 | 154.6 | 160.8 | 186.1 | 131.5 | 113.2 | 260.6 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -24.1 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -65.0 | -45.8 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -0.7 | 0.0 | 0.0 | -2.3 | -2.6 | -3.0 | -381.9 | -5.1 | -375.0 | 0.0 | 0.0 | -0.2 | -0.7 | -13.6 | -0.7 | -5.0 | -30.1 | |
| Debt Issued | 15.4 | 649.5 | -446.3 | 15.0 | 6.5 | 7.0 | 608.9 | 22.8 | 30.9 | 491.2 | 21.0 | 4.5 | 3.1 | 320.9 | 0.6 | -24.2 | 407.7 | |
| Issuance of Common Stock | 55.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 712.9 | 888.3 | 117.5 | 0.0 | 235.5 | 0.0 | 0.0 | |
| Repurchase of Common Stock | -75.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -66.1 | 0.0 | 0.0 | -85.8 | -16.0 | 3.0 | 613.0 | -69.6 | -13.1 | 507.1 | 14.2 | 39.8 | 68.9 | 760.2 | 77.5 | 34.0 | 33.6 | |
| Cash from Financing | -20.1 | 0.0 | 0.0 | -18.7 | -18.7 | 0.0 | 181.1 | -74.7 | -388.0 | 507.1 | 727.1 | 927.9 | 185.7 | 746.7 | 312.3 | 29.0 | 3.5 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.6 | |
| Debt Issued | 596.7 | -7.2 | 1.9 | -0.8 | 0.0 | -497.0 | 3.1 | 9.6 | 1.0 | 1.6 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.8 | 4.4 | |
| Repurchase of Common Stock | -38.8 | 0.0 | 0.0 | -38.8 | 0.0 | 0.0 | 0.0 | 0.0 | -3.9 | -4.5 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.9 | -0.2 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.8 | -0.8 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 277.8 | 368.8 | 187.7 | 30.6 | 137.3 | -61.9 | 211.7 | -56.5 | -104.0 | 189.7 | 11.3 | -478.4 | 306.7 | 388.3 | 134.3 | -41.8 | -79.1 | |
| Closing Cash Balance | 972.2 | 1,311.7 | 942.8 | 755.1 | 724.5 | 587.3 | 649.2 | 437.4 | 494.0 | 598.0 | 408.3 | 397.0 | 875.5 | 568.8 | 180.5 | 46.3 | 88.1 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 61.6 | 36.3 | 165.0 | 106.0 | 267.4 | -296.7 | 225.2 | -8.1 | -30.3 | 91.0 | |
| Closing Cash Balance | 1,311.7 | 1,250.1 | 1,213.8 | 1,048.8 | 942.8 | 675.4 | 972.2 | 747.0 | 755.1 | 785.4 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 212.8 | 725.0 | 475.4 | 51.6 | 44.4 | 185.3 | -52.2 | -115.1 | -124.4 | -208.0 | -376.2 | -449.3 | -192.4 | -124.8 | -27.0 | -135.5 | -30.7 | |
| Real Free Cash Flow | 3.4 | 543.5 | 273.9 | -155.5 | -151.9 | -12.0 | -241.9 | -275.0 | -273.2 | -348.2 | -510.9 | -560.9 | -280.6 | -190.9 | -74.3 | -179.4 | -69.1 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 58.9 | 340.2 | 168.2 | 157.6 | 165.3 | 200.3 | 96.9 | 12.9 | -9.2 | 112.2 | |
| Real Free Cash Flow | 12.0 | 291.0 | 120.6 | 119.9 | 113.4 | 156.8 | 49.0 | -45.4 | -64.1 | 63.8 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 30.6 | 69.4 | -1.4 |
| P/S | 3.3 | 11.5 | 9.4 |
| P/B | 1.8 | 5.1 | 5.2 |
| P/FCF | 19.7 | 20.5 | -1.5 |
| Market cap | $10.0 | $92.6 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 20.4 % | 0 % |
| Debt to Income | 171 % | 1828.5 % | 0 % |
| Debt to Free cash flow | 109.8 % | -28.7 % | 0 % |
| Interest expense percentage | 2 % | 293.5 % | 44.7 % |
| Current ratio | 4.8 | 4.8 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 5.8 % | -0.6 % | 0 % |
| ROA | 4.6 % | -0.5 % | 0 % |
| CapEx to Revenue | 0 % | 12 % | 0 % |
| RaD to Revenue | 0 % | 44.5 % | 0 % |
| ROEM | 1,059,622.7 | 437780.7 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 0 % | 78.3 % | 68.7 % |
| Operating margin | 0 % | -8.9 % | 35.5 % |
| Net margin | 0 % | -2.5 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 191.6 mil | 165.0 mil |
| Employee count | 3.0 tis | 1.7 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
